Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 258

1.

Clinical and Molecular Characteristics May Alter Treatment Strategies of Thyroid Malignancies in DICER1-syndrome.

van der Tuin K, de Kock L, Kamping EJ, Hannema SE, Pouwels MM, Niedziela M, van Wezel T, Hes FJ, Jongmans MC, Foulkes WD, Morreau H.

J Clin Endocrinol Metab. 2018 Sep 26. doi: 10.1210/jc.2018-00774. [Epub ahead of print]

PMID:
30260442
2.

Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content.

Sandberg TP, Oosting J, van Pelt GW, Mesker WE, Tollenaar RAEM, Morreau H.

Oncotarget. 2018 Jul 31;9(59):31502-31515. doi: 10.18632/oncotarget.25845. eCollection 2018 Jul 31.

3.

The theranostic target prostate-specific membrane antigen is expressed in medullary thyroid cancer.

Lodewijk L, Willems SM, Dreijerink KMA, de Keizer B, van Diest PJ, Schepers A, Morreau H, Bonenkamp HJ, Van Engen-van Grunsven IACH, Kruijff S, van Hemel BM, Links TP, Nieveen van Dijkum E, van Eeden S, Valk GD, Borel Rinkes IHM, Vriens MR.

Hum Pathol. 2018 Nov;81:245-254. doi: 10.1016/j.humpath.2018.06.035. Epub 2018 Jul 25. No abstract available.

PMID:
30055186
4.

Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations.

van Pelt GW, Kjær-Frifeldt S, van Krieken JHJM, Al Dieri R, Morreau H, Tollenaar RAEM, Sørensen FB, Mesker WE.

Virchows Arch. 2018 Oct;473(4):405-412. doi: 10.1007/s00428-018-2408-z. Epub 2018 Jul 20.

5.

High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers.

Ibrahim IS, Wasser MN, Wu Y, Inderson A, de Vos Tot Nederveen Cappel WH, Morreau H, Hes FJ, Veenendaal RA, Putter H, Feshtali S, van Mil AM, Gruis NA, Tollenaar RA, Bergman W, Bonsing BA, Vasen HFA.

Cancer Prev Res (Phila). 2018 Sep;11(9):551-556. doi: 10.1158/1940-6207.CAPR-18-0035. Epub 2018 Jul 10.

PMID:
29991580
6.

Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.

Ibrahim I, Sibinga Mulder BG, Bonsing B, Morreau H, Farina Sarasqueta A, Inderson A, Luelmo S, Feshtali S, Potjer TP, de Vos Tot Nederveen Cappel W, Wasser M, Vasen HFA.

Eur J Hum Genet. 2018 Aug;26(8):1227-1229. doi: 10.1038/s41431-018-0170-y. Epub 2018 May 16.

PMID:
29769629
7.

Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.

Ten Broeke SW, van Bavel TC, Jansen AML, Gómez-García E, Hes FJ, van Hest LP, Letteboer TGW, Olderode-Berends MJW, Ruano D, Spruijt L, Suerink M, Tops CM, van Eijk R, Morreau H, van Wezel T, Nielsen M.

Gastroenterology. 2018 Sep;155(3):844-851. doi: 10.1053/j.gastro.2018.05.020. Epub 2018 Jul 29.

PMID:
29758216
8.

RNA analysis of cancer predisposing genes in formalin-fixed paraffin-embedded tissue determines aberrant splicing.

Jansen AM, van der Klift HM, Roos MA, van Eendenburg JD, Tops CM, Wijnen JT, Hes FJ, Morreau H, van Wezel T.

Eur J Hum Genet. 2018 Aug;26(8):1143-1150. doi: 10.1038/s41431-018-0153-z. Epub 2018 Apr 30.

PMID:
29706640
9.

Dilemmas for the pathologist in the oncologic assessment of pancreatoduodenectomy specimens : An overview of different grossing approaches and the relevance of the histopathological characteristics in the oncologic assessment of pancreatoduodenectomy specimens.

Soer E, Brosens L, van de Vijver M, Dijk F, van Velthuysen ML, Farina-Sarasqueta A, Morreau H, Offerhaus J, Koens L, Verheij J.

Virchows Arch. 2018 Apr;472(4):533-543. doi: 10.1007/s00428-018-2321-5. Epub 2018 Mar 27. Review.

10.

The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact.

van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken JHJM, Tollenaar RAEM, Mesker WE.

Histopathology. 2018 Aug;73(2):197-206. doi: 10.1111/his.13489. Epub 2018 Mar 24. Review.

PMID:
29457843
11.

Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.

Schubert SA, Ruano D, Elsayed FA, Boot A, Crobach S, Sarasqueta AF, Wolffenbuttel B, van der Klauw MM, Oosting J, Tops CM, van Eijk R, Vasen HF, Vossen RH, Nielsen M, Castellví-Bel S, Ruiz-Ponte C, Tomlinson I, Dunlop MG, Vodicka P, Wijnen JT, Hes FJ, Morreau H, de Miranda NF, Sijmons RH, van Wezel T.

Br J Cancer. 2018 Jan;118(2):e4. doi: 10.1038/bjc.2017.380. Epub 2017 Oct 12. No abstract available.

12.

Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules.

de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, Morreau H, Schepers A, Smit J, Oyen WJG, Vriens D.

Endocr Rev. 2018 Apr 1;39(2):154-191. doi: 10.1210/er.2017-00133.

PMID:
29300866
13.

Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study.

van der Tuin K, Mensenkamp AR, Tops CMJ, Corssmit EPM, Dinjens WN, van de Horst-Schrivers ANA, Jansen JC, de Jong MM, Kunst HPM, Kusters B, Leter EM, Morreau H, van Nesselrooij BMP, Oldenburg RA, Spruijt L, Hes FJ, Timmers HJLM.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):438-445. doi: 10.1210/jc.2017-01762. Erratum in: J Clin Endocrinol Metab. 2018 May 1;103(5):2077.

PMID:
29177515
14.

Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice.

Leicher LW, Lammertink MHA, Offerman SR, Morreau H, de Jong MM, de Groot JWB, van Westreenen HL, Vasen HFA, de Vos Tot Nederveen Cappel WH.

Scand J Gastroenterol. 2018 May;53(5):632-636. doi: 10.1080/00365521.2017.1406534. Epub 2017 Nov 21.

PMID:
29161904
15.

Excluding Lynch syndrome in a female patient with metachronous DNA mismatch repair deficient colon- and ovarian cancer.

Crobach S, Jansen AML, Ligtenberg MJL, Koopmans M, Nielsen M, Hes FJ, Wijnen JT, Dinjens WNM, van Wezel T, Morreau H.

Fam Cancer. 2018 Jul;17(3):415-420. doi: 10.1007/s10689-017-0055-1.

16.

ROS-induced near-homozygous genomes in thyroid cancer.

Corver WE, Demmers J, Oosting J, Sahraeian S, Boot A, Ruano D, Wezel TV, Morreau H.

Endocr Relat Cancer. 2018 Jan;25(1):83-97. doi: 10.1530/ERC-17-0288. Epub 2017 Oct 24.

PMID:
29066502
17.

CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.

van der Tuin K, Tops CMJ, Adank MA, Cobben JM, Hamdy NAT, Jongmans MC, Menko FH, van Nesselrooij BPM, Netea-Maier RT, Oosterwijk JC, Valk GD, Wolffenbuttel BHR, Hes FJ, Morreau H.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4534-4540. doi: 10.1210/jc.2017-01249.

PMID:
29040582
18.

Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.

Boot A, Oosting J, van Eendenburg JDH, Kuppen PJK, Morreau H, van Wezel T.

PLoS One. 2017 Sep 20;12(9):e0184900. doi: 10.1371/journal.pone.0184900. eCollection 2017.

19.

Diagnostic value of targeted next-generation sequencing in patients with suspected pancreatic or periampullary cancer.

Sibinga Mulder BG, Mieog JSD, Farina Sarasqueta A, Handgraaf HJ, Vasen HFA, Swijnenburg RJ, Luelmo SAC, Feshtali S, Inderson A, Vahrmeijer AL, Bonsing BA, Wezel TV, Morreau H.

J Clin Pathol. 2018 Mar;71(3):246-252. doi: 10.1136/jclinpath-2017-204607. Epub 2017 Aug 3.

PMID:
28775172
20.

Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.

Schubert SA, Ruano D, Elsayed FA, Boot A, Crobach S, Sarasqueta AF, Wolffenbuttel B, van der Klauw MM, Oosting J, Tops CM, van Eijk R, Vasen HF, Vossen RH, Nielsen M, Castellví-Bel S, Ruiz-Ponte C, Tomlinson I, Dunlop MG, Vodicka P, Wijnen JT, Hes FJ, Morreau H, de Miranda NF, Sijmons RH, van Wezel T.

Br J Cancer. 2017 Sep 5;117(6):1215-1223. doi: 10.1038/bjc.2017.240. Epub 2017 Jul 25. Erratum in: Br J Cancer. 2018 Jan;118(2):e4.

21.

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.

de Geus SW, Baart VM, Boonstra MC, Kuppen PJ, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJ, Vahrmeijer AL, Sier CF.

Biomark Insights. 2017 Jun 22;12:1177271917715443. doi: 10.1177/1177271917715443. eCollection 2017. Review.

22.

Quantitative NMR analysis of intra- and extracellular metabolism of mammalian cells: A tutorial.

Kostidis S, Addie RD, Morreau H, Mayboroda OA, Giera M.

Anal Chim Acta. 2017 Aug 8;980:1-24. doi: 10.1016/j.aca.2017.05.011. Epub 2017 May 24. Review.

23.

Statin Use After Diagnosis of Colon Cancer and Patient Survival.

Voorneveld PW, Reimers MS, Bastiaannet E, Jacobs RJ, van Eijk R, Zanders MMJ, Herings RMC, van Herk-Sukel MPP, Kodach LL, van Wezel T, Kuppen PJK, Morreau H, van de Velde CJH, Hardwick JCH, Liefers GJ.

Gastroenterology. 2017 Aug;153(2):470-479.e4. doi: 10.1053/j.gastro.2017.05.011. Epub 2017 May 13.

PMID:
28512021
24.

Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis.

Ghorbanoghli Z, Bastiaansen BA, Langers AM, Nagengast FM, Poley JW, Hardwick JC, Koornstra JJ, Sanduleanu S, de Vos Tot Nederveen Cappel WH, Witteman BJ, Morreau H, Dekker E, Vasen HF.

J Med Genet. 2018 Jan;55(1):11-14. doi: 10.1136/jmedgenet-2017-104545. Epub 2017 May 10.

PMID:
28490611
25.

Validation of full-field optical coherence tomography in distinguishing malignant and benign tissue in resected pancreatic cancer specimens.

van Manen L, Stegehuis PL, Fariña-Sarasqueta A, de Haan LM, Eggermont J, Bonsing BA, Morreau H, Lelieveldt BPF, van de Velde CJH, Vahrmeijer AL, Dijkstra J, Mieog JSD.

PLoS One. 2017 Apr 17;12(4):e0175862. doi: 10.1371/journal.pone.0175862. eCollection 2017.

26.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
27.

Genomic profiling reveals mutational landscape in parathyroid carcinomas.

Pandya C, Uzilov AV, Bellizzi J, Lau CY, Moe AS, Strahl M, Hamou W, Newman LC, Fink MY, Antipin Y, Yu W, Stevenson M, Cavaco BM, Teh BT, Thakker RV, Morreau H, Schadt EE, Sebra R, Li SD, Arnold A, Chen R.

JCI Insight. 2017 Mar 23;2(6):e92061. doi: 10.1172/jci.insight.92061.

28.

Toward optical guidance during endoscopic ultrasound-guided fine needle aspirations of pancreatic masses using single fiber reflectance spectroscopy: a feasibility study.

Stegehuis PL, Boogerd LS, Inderson A, Veenendaal RA, van Gerven P, Bonsing BA, Sven Mieog J, Amelink A, Veselic M, Morreau H, van de Velde CJ, Lelieveldt BP, Dijkstra J, Robinson DJ, Vahrmeijer AL.

J Biomed Opt. 2017 Feb 1;22(2):24001. doi: 10.1117/1.JBO.22.2.024001.

PMID:
28170030
29.

The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis.

Frouws MA, Reimers MS, Swets M, Bastiaannet E, Prinse B, van Eijk R, Lemmens VE, van Herk-Sukel MP, van Wezel T, Kuppen PJ, Morreau H, van de Velde CJ, Liefers GJ.

PLoS One. 2017 Jan 26;12(1):e0170775. doi: 10.1371/journal.pone.0170775. eCollection 2017.

30.

Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.

Schneider TC, de Wit D, Links TP, van Erp NP, van der Hoeven JJ, Gelderblom H, Roozen IC, Bos M, Corver WE, van Wezel T, Smit JW, Morreau H, Guchelaar HJ, Kapiteijn E.

J Clin Endocrinol Metab. 2017 Feb 1;102(2):698-707. doi: 10.1210/jc.2016-2525. Erratum in: J Clin Endocrinol Metab. 2017 Jun 1;102(6):2125.

PMID:
27870581
31.

Distinct Patterns of Somatic Mosaicism in the APC Gene in Neoplasms From Patients With Unexplained Adenomatous Polyposis.

Jansen AM, Crobach S, Geurts-Giele WR, van den Akker BE, Garcia MV, Ruano D, Nielsen M, Tops CM, Wijnen JT, Hes FJ, van Wezel T, Dinjens WN, Morreau H.

Gastroenterology. 2017 Feb;152(3):546-549.e3. doi: 10.1053/j.gastro.2016.10.040. Epub 2016 Nov 2.

PMID:
27816598
32.

Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.

de Geus SW, Boogerd LS, Swijnenburg RJ, Mieog JS, Tummers WS, Prevoo HA, Sier CF, Morreau H, Bonsing BA, van de Velde CJ, Vahrmeijer AL, Kuppen PJ.

Mol Imaging Biol. 2016 Dec;18(6):807-819.

33.

Practical guidance for mismatch repair-deficiency testing in endometrial cancer.

Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, Church DN, Morreau H, Smit VTHBM, van Wezel T, Bosse T.

Ann Oncol. 2017 Jan 1;28(1):96-102. doi: 10.1093/annonc/mdw542.

PMID:
27742654
34.

Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer.

Sibinga Mulder BG, Mieog JS, Handgraaf HJ, Farina Sarasqueta A, Vasen HF, Potjer TP, Swijnenburg RJ, Luelmo SA, Feshtali S, Inderson A, Vahrmeijer AL, Bonsing BA, van Wezel T, Morreau H.

J Clin Pathol. 2017 Feb;70(2):174-178. doi: 10.1136/jclinpath-2016-203928. Epub 2016 Sep 26.

PMID:
27672215
35.

Epithelial-mesenchymal transition and nuclear β-catenin induced by conditional intestinal disruption of Cdh1 with Apc is E-cadherin EC1 domain dependent.

Matheson J, Bühnemann C, Carter EJ, Barnes D, Hoppe HJ, Hughes J, Cobbold S, Harper J, Morreau H, Surakhy M, Hassan AB.

Oncotarget. 2016 Oct 25;7(43):69883-69902. doi: 10.18632/oncotarget.11513.

36.

Somatic mutation profiles in primary colorectal cancers and matching ovarian metastases: Identification of driver and passenger mutations.

Crobach S, Ruano D, van Eijk R, Schrumpf M; PALGA group, Fleuren G, van Wezel T, Morreau H.

J Pathol Clin Res. 2016 Apr 15;2(3):166-74. doi: 10.1002/cjp2.45. eCollection 2016 Jul.

37.

Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer.

Ibrahim IS, Bonsing BA, Swijnenburg RJ, Welling L, Veenendaal RA, Wasser MN, Morreau H, Inderson A, Vasen HF.

Fam Cancer. 2017 Jan;16(1):111-115. doi: 10.1007/s10689-016-9915-3.

38.

Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers.

Hoekstra AS, Addie RD, Ras C, Seifar RM, Ruivenkamp CA, Briaire-de Bruijn IH, Hes FJ, Jansen JC, Corssmit EP, Corver WE, Morreau H, Bovée JV, Bayley JP, Devilee P.

Hum Mol Genet. 2016 Sep 1;25(17):3715-3728. doi: 10.1093/hmg/ddw218. Epub 2016 Jul 8.

PMID:
27402879
39.

Identification of familial colorectal cancer and hereditary colorectal cancer syndromes through the Dutch population-screening program: results ofa pilot study.

van Erp SJ, Leicher LW, Hennink SD, Ghorbanoghli Z, Breg SA, Morreau H, Nielsen M, Hardwick JC, Roukema JA, Langers AM, de Vos Tot Nederveen Cappel WH, Vasen HF.

Scand J Gastroenterol. 2016 Oct;51(10):1227-32. doi: 10.1080/00365521.2016.1193219. Epub 2016 Jun 16.

40.

Whole Gene Capture Analysis of 15 CRC Susceptibility Genes in Suspected Lynch Syndrome Patients.

Jansen AM, Geilenkirchen MA, van Wezel T, Jagmohan-Changur SC, Ruano D, van der Klift HM, van den Akker BE, Laros JF, van Galen M, Wagner A, Letteboer TG, Gómez-García EB, Tops CM, Vasen HF, Devilee P, Hes FJ, Morreau H, Wijnen JT.

PLoS One. 2016 Jun 14;11(6):e0157381. doi: 10.1371/journal.pone.0157381. eCollection 2016.

41.

Imprinted survival genes preclude loss of heterozygosity of chromosome 7 in cancer cells.

Boot A, Oosting J, de Miranda NF, Zhang Y, Corver WE, van de Water B, Morreau H, van Wezel T.

J Pathol. 2016 Sep;240(1):72-83. doi: 10.1002/path.4756.

PMID:
27265324
42.

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.

Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK.

J Clin Oncol. 2016 Jun 10;34(17):2010-9. doi: 10.1200/JCO.2015.64.0730. Epub 2016 Apr 25.

PMID:
27114589
43.

Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer.

Plantinga TS, Tesselaar MH, Morreau H, Corssmit EP, Willemsen BK, Kusters B, van Engen-van Grunsven AC, Smit JW, Netea-Maier RT.

Autophagy. 2016 Jul 2;12(7):1195-205. doi: 10.1080/15548627.2016.1174802. Epub 2016 Apr 22.

44.

Characterization of novel low passage primary and metastatic colorectal cancer cell lines.

Boot A, van Eendenburg J, Crobach S, Ruano D, Speetjens F, Calame J, Oosting J, Morreau H, van Wezel T.

Oncotarget. 2016 Mar 22;7(12):14499-509. doi: 10.18632/oncotarget.7391.

45.

Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing.

Bolognesi C, Forcato C, Buson G, Fontana F, Mangano C, Doffini A, Sero V, Lanzellotto R, Signorini G, Calanca A, Sergio M, Romano R, Gianni S, Medoro G, Giorgini G, Morreau H, Barberis M, Corver WE, Manaresi N.

Sci Rep. 2016 Feb 11;6:20944. doi: 10.1038/srep20944.

46.

(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.

Schneider TC, Kapiteijn E, van Wezel T, Smit JWA, van der Hoeven JJM, Morreau H.

BMC Cancer. 2016 Jan 19;16:31. doi: 10.1186/s12885-016-2060-4.

47.

Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers.

Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, Wagner A, Letteboer TG, Gómez-García EB, Devilee P, Wijnen JT, Hes FJ, Morreau H.

Eur J Hum Genet. 2016 Jul;24(7):1089-92. doi: 10.1038/ejhg.2015.252. Epub 2015 Dec 9.

48.

Recurrent Coding Sequence Variation Explains Only A Small Fraction of the Genetic Architecture of Colorectal Cancer.

Timofeeva MN, Kinnersley B, Farrington SM, Whiffin N, Palles C, Svinti V, Lloyd A, Gorman M, Ooi LY, Hosking F, Barclay E, Zgaga L, Dobbins S, Martin L, Theodoratou E, Broderick P, Tenesa A, Smillie C, Grimes G, Hayward C, Campbell A, Porteous D, Deary IJ, Harris SE, Northwood EL, Barrett JH, Smith G, Wolf R, Forman D, Morreau H, Ruano D, Tops C, Wijnen J, Schrumpf M, Boot A, Vasen HF, Hes FJ, van Wezel T, Franke A, Lieb W, Schafmayer C, Hampe J, Buch S, Propping P, Hemminki K, Försti A, Westers H, Hofstra R, Pinheiro M, Pinto C, Teixeira M, Ruiz-Ponte C, Fernández-Rozadilla C, Carracedo A, Castells A, Castellví-Bel S, Campbell H, Bishop DT, Tomlinson IP, Dunlop MG, Houlston RS.

Sci Rep. 2015 Nov 10;5:16286. doi: 10.1038/srep16286.

49.

Randomized Comparison of Surveillance Intervals in Familial Colorectal Cancer.

Hennink SD, van der Meulen-de Jong AE, Wolterbeek R, Crobach AS, Becx MC, Crobach WF, van Haastert M, Ten Hove WR, Kleibeuker JH, Meijssen MA, Nagengast FM, Rijk MC, Salemans JM, Stronkhorst A, Tuynman HA, Vecht J, Verhulst ML, de Vos Tot Nederveen Cappel WH, Walinga H, Weinhardt OK, Westerveld D, Witte AM, Wolters HJ, Cats A, Veenendaal RA, Morreau H, Vasen HF.

J Clin Oncol. 2015 Dec 10;33(35):4188-93. doi: 10.1200/JCO.2015.62.2035. Epub 2015 Nov 2.

PMID:
26527788
50.

A novel RET/PTC variant detected in a pediatric patient with papillary thyroid cancer without ionization history.

Halkova T, Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Sykorova P, Vlcek P, Reboun M, Katra R, Kodetova D, Schrumpf M, van Wezel T, Morreau H, Bendlova B.

Hum Pathol. 2015 Dec;46(12):1962-9. doi: 10.1016/j.humpath.2015.08.013. Epub 2015 Sep 15.

PMID:
26472164

Supplemental Content

Loading ...
Support Center